Georgia Tech Research Corporation Atlanta United States
There are currently no treatment methods on the market for modifying OA only drugs that help relieve pain and inflammation but do not address the underlying disease, allowing it to continue destroying joint tissues. When joint function becomes severely impaired and other management strategies are ineffective, arthroscopic or joint replacement surgeries become the only options for patients. More than 50 of people worldwide who are over 65 years of age show radiological evidence of OA. These patients and younger populations who are susceptible to OA onset due to sports injuries or other factors could significantly benefit from the development of strategies to mitigate disease progression. Furthermore, post-traumatic OA experienced by military personnel injured on the battlefield is a highly accelerated process, likely because these combat injuries are complicated by factors that are associated with greater risk including bone loss, surrounding soft tissue damage, and infection. In these combat-related cases, post-traumatic OA typically manifests less than 2 years after injury compared to post-traumatic OA resulting from sports injuries that takes about 10 years to develop.The goals of this work are to test the ability of a novel therapeutic to hinder the progression of post-traumatic osteoarthritis. This debilitating joint condition more severely affects military service personnel who have sustained injuries in combat resulting from high energy impacts such as explosions, fragment projectiles, and gunshot wounds. The therapeutic we propose is derived from human amniotic membrane, which has shown promise in clinical studies for various regenerative applications.